Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Rapt Therapeutics Inc (RAPT)

Rapt Therapeutics Inc (RAPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,013,503
  • Shares Outstanding, K 29,488
  • Annual Sales, $ 5,040 K
  • Annual Income, $ -52,890 K
  • 60-Month Beta 0.04
  • Price/Sales 200.13
  • Price/Cash Flow N/A
  • Price/Book 4.14
Trade RAPT with:

Options Overview Details

View History
  • Implied Volatility 73.41%
  • Historical Volatility 53.63%
  • IV Percentile 4%
  • IV Rank 1.67%
  • IV High 275.77% on 11/09/20
  • IV Low 69.97% on 08/20/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 223
  • Volume Avg (30-Day) 156
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,120
  • Open Int (30-Day) 2,780

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.60
  • Number of Estimates 4
  • High Estimate -0.58
  • Low Estimate -0.61
  • Prior Year -0.60
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.32 +9.72%
on 08/30/21
40.67 -15.49%
on 09/17/21
+2.45 (+7.68%)
since 08/24/21
3-Month
29.08 +18.19%
on 07/15/21
40.67 -15.49%
on 09/17/21
-0.57 (-1.63%)
since 06/24/21
52-Week
14.63 +134.93%
on 11/16/20
43.26 -20.55%
on 06/15/21
+6.16 (+21.84%)
since 09/24/20

Most Recent Stories

More News
RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with...

RAPT : 34.37 (+0.44%)
RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with...

RAPT : 34.37 (+0.44%)
RAPT Therapeutics to Present at Upcoming Investor Conferences

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with...

RAPT : 34.37 (+0.44%)
RAPT THERAPTICS (RAPT) Reports Q2 Loss, Lags Revenue Estimates

RAPT THERAPTICS (RAPT) delivered earnings and revenue surprises of -1.61% and -39.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

RAPT : 34.37 (+0.44%)
Analysts Estimate RAPT THERAPTICS (RAPT) to Report a Decline in Earnings: What to Look Out for

RAPT THERAPTICS (RAPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RAPT : 34.37 (+0.44%)
Thinking about buying stock in Anavex Life Sciences, Globalstar, Rapt Therapeutics, Aytu Biopharma, or Evofem Biosciences?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVXL, GSAT, RAPT, AYTU, and EVFM.

GSAT : 1.6800 (-5.62%)
EVFM : 0.7773 (-0.49%)
RAPT : 34.37 (+0.44%)
AVXL : 18.74 (-2.85%)
AYTU : 2.97 (-1.33%)
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with...

JPM : 163.04 (+1.15%)
RAPT : 34.37 (+0.44%)
RAPT Reports Positive Data From Atopic Dermatitis Study

RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.

REGN : 638.90 (-1.18%)
SNY : 47.94 (-1.60%)
RGEN : 323.26 (-0.29%)
RAPT : 34.37 (+0.44%)
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with...

JPM : 163.04 (+1.15%)
RAPT : 34.37 (+0.44%)
RAPT Therapeutics (RAPT) is in Overbought Territory: What's Next?

RAPT Therapeutics (RAPT) has moved higher as of late, but there could definitely be trouble on the horizon for this company

RAPT : 34.37 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

RAPT Therapeutics Inc. is a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for oncology and inflammatory diseases. The company's drug candidate consists of FLX475 for the treatment of tumors and RPT193,...

See More

Key Turning Points

3rd Resistance Point 36.74
2nd Resistance Point 35.78
1st Resistance Point 35.08
Last Price 34.37
1st Support Level 33.42
2nd Support Level 32.46
3rd Support Level 31.76

See More

52-Week High 43.26
Last Price 34.37
Fibonacci 61.8% 32.32
Fibonacci 50% 28.94
Fibonacci 38.2% 25.57
52-Week Low 14.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar